26 search results for: disease control
Emerging Perspectives on the Disease Burden and Management of Children With Atopic Dermatitis
This video of the October 2024 ADVENT symposium at EAPS in Vienna, Austria features Drs Christine Bangert, Mark Boguniewicz, and Perla Lansang as they discuss the inflammatory processes driven by type 2 cytokines that lead to AD and atopic comorbidities, the multidimensional and cumulative disease burden associated with AD and its comorbidities, and the current and emerging treatment options for children with AD uncontrolled with topical therapy
CLCI in Atopic Dermatitis Infographic
This infographic highlights how uncontrolled moderate‑to‑severe atopic dermatitis (AD) can lead to Cumulative Life Course Impairment (CLCI) by contributing to ongoing physical, psychological, and social burdens such as itch and sleep loss, impaired bone growth and mental health challenges. It emphasizes the importance of early and effective disease control to help reduce long‑term impact on patients.
Beyond Signs and Symptoms: Broadening Treatment Goals in Dermatology
Dr Lawrence Eichenfield explores the broadening of treatment goals for long-term disease control, highlighting the importance of this approach in atopic dermatitis. Drs Culton, Elmariah, and Hawkes expand the discussion to further examine specific management goals unique to each skin disease (bullous pemphigoid, prurigo nodularis, and chronic spontaneous urticaria).
ADVENT On Air | Expert Discussions in Dermatology
Listen to the latest updates in type 2 inflammatory science and associated skin diseases, brought to you by leading dermatology experts in the field. ADVENT On Air podcasts feature scientific conversations that explore new research into the pathophysiology, clinical features, and disease burden for a range of dermatological diseases linked to type 2 inflammation, including atopic dermatitis (AD) and prurigo nodularis (PN). Hear new insights revealed through expert-led conversations below or in your preferred podcast app.
ADVENT On Air | Exploring The Urgency to Treat in Atopic Dermatitis
Professor Lisa Beck explores the chronic and persistent burden of atopic dermatitis (AD) as well as the concept of early intervention in patients with AD.
Beyond Clinical Control: Targeting Type 2 Inflammation for Improved Patient Outcomes
Prof Alan Irvine presents the latest clinical and real-world evidence supporting the potential for disease modification in atopic dermatitis, at EADV 2025.
Understanding Barriers to Advanced Systemic Therapy in AD
Dr. Jean-David Bouaziz highlights a study describing barriers to initiating advanced systemic therapy for AD at EADV 2025
Early Intervention May Have the Potential to Alter the Trajectory of Atopic Dermatitis
Dr. Lawrence Eichenfield discusses the meaning of "early intervention" and its potential implications in atopic dermatitis.
Cumulative Impact of Uncontrolled Atopic Dermatitis: Skin Inflammation as the Tip of the Iceberg
Prof Jean-David Bouaziz describes the multifaceted burden of atopic dermatitis, beyond what can be seen on the skin, at EADV 2025.
